ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

PT Kalbe Farma Tbk

  • 1,560.00 IDR
  • -35.00
  • -2.19%
  • Indonesia
    Apr 20, 2018
  • Ticker
    JKT(KLBF)
  • Prev. close
    1,595
  • Market cap (IDR)
    74,765.80B
  • Market cap (USD)
    5,387.56M
  • Shares
    46,875.10M

Company Background

Indonesia's Kalbe Farma is one of Southeast Asia's largest pharmaceutical companies. It has a diverse lineup of products, ranging from prescription medicine to vitamins to energy drinks.

The company has its own distribution network that carries products to a large number of retail outlets. It also distributes products for major foreign pharmaceutical companies, including Astellas Pharma of Japan and Baxter of the U.S.

Kalbe Farma was launched out of a garage by Boenjamin Setiawan, who is now in his 80s, and his brothers. Setiawan has left the board of directors and now serves as honorary chairman. His niece, Bernadette Ruth Irawati Setiady, has served as president since 2008. The group of founders holds a significant stake in the company.

Kalbe Farma has been expanding its consumer sector, acquiring local health-drink producer Hale International in 2012. The company exports some of its products to neighboring countries.

Business Summary

PT Kalbe Farma Tbk engages in the development, production, distribution, and trade of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical segment offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores throughout Indonesia. The Consumer Health segment provides over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals segment sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistics segment maintains distribution of the company's and third party principal's products across Indonesia, and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.

Financial Highlights

Dec 2017 IDRUSD
Revenue20,182.12B1,508.17M
Gross Profit9,531.04B712.23M
Operating income3,147.95B235.24M
Income before tax3,241.18B242.20M
Net income2,403.60B179.61M
EBITDA3,596.49B268.76M
Diluted EPS51.280.00
Dividends Per Share----
Total Assets16,616.23B1,224.70M
Total liabilities2,722.20B200.64M
Total equity13,280.80B978.86M
Operating cash flow2,079.54B155.40M
Currency in IDRCurrency in USD

Historical Data

 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 16,002.13B 17,368.53B 17,887.46B 19,374.23B 20,182.12B
Gross Profit 7,526.66B 8,284.22B 8,374.19B 9,258.50B 9,531.04B
Operating income 2,548.91B 2,669.38B 2,561.74B 2,976.16B 3,147.95B
Income before tax 2,574.85B 2,765.59B 2,720.88B 3,091.18B 3,241.18B
Net income 1,919.50B 2,066.02B 2,004.23B 2,299.73B 2,403.60B
EBITDA 2,823.59B 3,010.06B 2,950.45B 3,416.92B 3,596.49B
Diluted EPS 41 44.08 42.76 49.06 51.28
Dividends Per Share 17 19 19 22 --
Total Assets 11,315.06B 12,439.26B 13,696.41B 15,226.00B 16,616.23B
Total liabilities 2,815.10B 2,675.16B 2,758.13B 2,762.16B 2,722.20B
Total equity 8,108.24B 9,330.07B 10,465.12B 11,909.26B 13,280.80B
Operating cash flow 954,915.99M 2,325.24B 2,513.23B 2,233.38B 2,079.54B
 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 1,531.59M 1,463.99M 1,335.16M 1,456.66M 1,508.17M
Gross Profit 720.39M 698.27M 625.06M 696.10M 712.23M
Operating income 243.96M 225.00M 191.21M 223.76M 235.24M
Income before tax 246.44M 233.11M 203.09M 232.41M 242.20M
Net income 183.72M 174.14M 149.60M 172.90M 179.61M
EBITDA 270.25M 253.71M 220.22M 256.90M 268.76M
Diluted EPS 0.00 0.00 0.00 0.00 0.00
Dividends Per Share 0.00 0.00 0.00 0.00 --
Total Assets 929.75M 1,004.38M 993.57M 1,130.15M 1,224.70M
Total liabilities 231.31M 216.00M 200.08M 205.02M 200.64M
Total equity 666.24M 753.33M 759.16M 883.96M 978.86M
Operating cash flow 91.39M 195.99M 187.59M 167.91M 155.40M

Valuation Measures

Dec 2017
PER32.95
ROA15.09%
ROE19.08%
Operating margin15.59%
Profit margin11.90%

Key executives

  • President Director: Bernadette Ruth Setiady
  • Head-Corporate Finance, Accounting & Tax: Bernadus Karmin Winata
  • Head-Corporate Information Technology & System: Dino Bramanto
  • Director: Bujung Nugroho
  • Director: Ongkie Tedjasurja

Shareholders

  • SWAN KHOUW LIP (10.1%)
  • SETIAWAN BOENJAMIN (9.6%)
  • VERONICA GERDA (9.5%)
  • KARMILA MARIA (9.4%)
  • HARSHINI THERESIA (9.2%)
  • ARYANTO FRANCISCUS BING (8.6%)
  • First State Investment Management (UK) Ltd. (1.7%)
  • BlackRock Fund Advisors (1.3%)
  • The Vanguard Group, Inc. (1.3%)
  • PT Schroder Investment Management Indonesia (0.9%)

Contact Details

  • Website:http://www.kalbe.co.id
  • Address: Gedung KALBE, Jalan Let. Jend. Suprapto Kavling 4, Jakarta, 10510, Indonesia
  • Phone: +62.21.4287.3888

Related Companies

  • PT Karsa Lintas Buwana
  • Kalbe Malaysia Sdn. Bhd.
  • PT Kalbio Global Medika
  • Innogene Kalbiotech Pte Ltd.
  • PT Kalbe Milko Indonesia
  • Kalbe Vision Pte Ltd.
  • PT Bifarma Adiluhung
  • PT Hale International
  • PT Finusolprima Farma International
  • PT Saka Farma Laboratories
  • PT Hexpharm Jaya Laboratories
  • PT Dankos Farma
  • PT Bintang Toedjoe
  • PT Kalbe Morinaga Indonesia
  • PT Sanghiang Perkasa
  • Kalbe International Pte Ltd.
  • PT Enseval Putera Megatrading Tbk

Competitors

  • LT Group, Inc.
Last Updated on 20 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media